BANCA MEDIOLANUM SPA (BMED.MI) Stock Fundamental Analysis
BIT:BMED - Euronext Milan - IT0004776628 - Common Stock - Currency: EUR
We assign a fundamental rating of 4 out of 10 to BMED. BMED was compared to 51 industry peers in the Financial Services industry. BMED has a medium profitability rating, but doesn't score so well on its financial health evaluation. BMED has a correct valuation and a medium growth rate. BMED also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
BMED had positive earnings in the past year.
BMED had a positive operating cash flow in the past year.
BMED had positive earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: BMED reported negative operating cash flow in multiple years.
1.2 Ratios
BMED has a Return On Assets (1.82%) which is comparable to the rest of the industry.
BMED has a Return On Equity of 38.86%. This is amongst the best in the industry. BMED outperforms 88.24% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.82% | ||
| ROE | 38.86% | ||
| ROIC | N/A |
ROA(3y)1.24%
ROA(5y)1.08%
ROE(3y)27.98%
ROE(5y)24.91%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BMED's Profit Margin of 16.26% is fine compared to the rest of the industry. BMED outperforms 68.63% of its industry peers.
In the last couple of years the Profit Margin of BMED has grown nicely.
BMED does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 16.26% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y16.85%
PM growth 5Y14.52%
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
BMED does not have a ROIC to compare to the WACC, probably because it is not profitable.
BMED has less shares outstanding than it did 1 year ago.
BMED has more shares outstanding than it did 5 years ago.
BMED has a better debt/assets ratio than last year.
2.2 Solvency
BMED has a debt to FCF ratio of 6.56. This is a slightly negative value and a sign of low solvency as BMED would need 6.56 years to pay back of all of its debts.
With a Debt to FCF ratio value of 6.56, BMED perfoms like the industry average, outperforming 54.90% of the companies in the same industry.
BMED has a Debt/Equity ratio of 1.79. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 1.79, BMED is doing worse than 66.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.79 | ||
| Debt/FCF | 6.56 | ||
| Altman-Z | N/A |
ROIC/WACCN/A
WACC7.37%
2.3 Liquidity
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | N/A | ||
| Quick Ratio | N/A |
3. Growth
3.1 Past
BMED shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.00%, which is quite impressive.
The Earnings Per Share has been growing by 14.21% on average over the past years. This is quite good.
Looking at the last year, BMED shows a very strong growth in Revenue. The Revenue has grown by 44.99%.
Measured over the past years, BMED shows a small growth in Revenue. The Revenue has been growing by 0.11% on average per year.
EPS 1Y (TTM)36%
EPS 3Y15.94%
EPS 5Y14.21%
EPS Q2Q%81.82%
Revenue 1Y (TTM)44.99%
Revenue growth 3Y-0.53%
Revenue growth 5Y0.11%
Sales Q2Q%11.52%
3.2 Future
Based on estimates for the next years, BMED will show a decrease in Earnings Per Share. The EPS will decrease by -4.80% on average per year.
The Revenue is expected to grow by 1.66% on average over the next years.
EPS Next Y-19.14%
EPS Next 2Y-8.65%
EPS Next 3Y-4.8%
EPS Next 5YN/A
Revenue Next Year-4.39%
Revenue Next 2Y1.38%
Revenue Next 3Y1.66%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
BMED is valuated reasonably with a Price/Earnings ratio of 8.77.
Compared to the rest of the industry, the Price/Earnings ratio of BMED indicates a somewhat cheap valuation: BMED is cheaper than 66.67% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of BMED to the average of the S&P500 Index (28.79), we can say BMED is valued rather cheaply.
BMED is valuated reasonably with a Price/Forward Earnings ratio of 10.87.
Based on the Price/Forward Earnings ratio, BMED is valued a bit cheaper than the industry average as 66.67% of the companies are valued more expensively.
BMED is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 21.38, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.77 | ||
| Fwd PE | 10.87 |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, BMED is valued a bit cheaper than 72.55% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.95 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as BMED's earnings are expected to decrease with -4.80% in the coming years.
PEG (NY)N/A
PEG (5Y)0.62
EPS Next 2Y-8.65%
EPS Next 3Y-4.8%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 7.79%, BMED is a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 3.81, BMED pays a better dividend. On top of this BMED pays more dividend than 94.12% of the companies listed in the same industry.
BMED's Dividend Yield is rather good when compared to the S&P500 average which is at 2.47.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 7.79% |
5.2 History
On average, the dividend of BMED grows each year by 14.04%, which is quite nice.
Dividend Growth(5Y)14.04%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
BMED pays out 37.38% of its income as dividend. This is a sustainable payout ratio.
DP37.38%
EPS Next 2Y-8.65%
EPS Next 3Y-4.8%
BIT:BMED (4/25/2025, 7:00:00 PM)
13.15
+0.32 (+2.49%)
Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryFinancial Services
Earnings (Last)
Earnings (Next)
Inst Owners9.82%
Inst Owner ChangeN/A
Ins Owners40.28%
Ins Owner ChangeN/A
Market Cap9.80B
Analysts87.06
Price Target15.31 (16.43%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 7.79% |
Yearly Dividend0.79
Dividend Growth(5Y)14.04%
DP37.38%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)22.19%
Min EPS beat(2)1.77%
Max EPS beat(2)42.6%
EPS beat(4)3
Avg EPS beat(4)10.87%
Min EPS beat(4)-1.3%
Max EPS beat(4)42.6%
EPS beat(8)6
Avg EPS beat(8)7.49%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-32.79%
Min Revenue beat(2)-44.68%
Max Revenue beat(2)-20.91%
Revenue beat(4)0
Avg Revenue beat(4)-25.64%
Min Revenue beat(4)-44.68%
Max Revenue beat(4)-12.99%
Revenue beat(8)0
Avg Revenue beat(8)-20.01%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.7%
PT rev (3m)16.36%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-1.53%
EPS NY rev (3m)-0.82%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-1.28%
Revenue NY rev (3m)-0.93%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.77 | ||
| Fwd PE | 10.87 | ||
| P/S | 1.02 | ||
| P/FCF | 8.95 | ||
| P/OCF | 8.51 | ||
| P/B | 2.43 | ||
| P/tB | 2.57 | ||
| EV/EBITDA | N/A |
EPS(TTM)1.5
EY11.41%
EPS(NY)1.21
Fwd EY9.2%
FCF(TTM)1.47
FCFY11.18%
OCF(TTM)1.55
OCFY11.76%
SpS12.91
BVpS5.4
TBVpS5.12
PEG (NY)N/A
PEG (5Y)0.62
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.82% | ||
| ROE | 38.86% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 16.26% | ||
| GM | N/A | ||
| FCFM | 11.39% |
ROA(3y)1.24%
ROA(5y)1.08%
ROE(3y)27.98%
ROE(5y)24.91%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y16.85%
PM growth 5Y14.52%
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.11
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.79 | ||
| Debt/FCF | 6.56 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 95.34% | ||
| Cap/Sales | 0.59% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | 70.03% | ||
| Current Ratio | N/A | ||
| Quick Ratio | N/A | ||
| Altman-Z | N/A |
F-Score7
WACC7.37%
ROIC/WACCN/A
Cap/Depr(3y)87.43%
Cap/Depr(5y)95.87%
Cap/Sales(3y)2.01%
Cap/Sales(5y)1.62%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36%
EPS 3Y15.94%
EPS 5Y14.21%
EPS Q2Q%81.82%
EPS Next Y-19.14%
EPS Next 2Y-8.65%
EPS Next 3Y-4.8%
EPS Next 5YN/A
Revenue 1Y (TTM)44.99%
Revenue growth 3Y-0.53%
Revenue growth 5Y0.11%
Sales Q2Q%11.52%
Revenue Next Year-4.39%
Revenue Next 2Y1.38%
Revenue Next 3Y1.66%
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y160.66%
FCF growth 3Y8.9%
FCF growth 5Y27.28%
OCF growth 1Y165.69%
OCF growth 3Y8.21%
OCF growth 5Y25.97%